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Background: Epidemiological evidence of relationships between endometriosis and epithelial ovarian cancer (EOC)
has been obtained mainly from Western countries. Our goal was to determine the risk of EOC due to endometriosis
in Taiwanese women.
Methods: A retrospective cohort study was performed by linking to the National Health Insurance Research
Database (NHIRD) of Taiwan. A total of 5,945 women with a new surgico-pathological diagnosis of endometriosis
from 2000 to 2010 and 23,780 multivariable-matched controls (1:4) were selected. The Cox regression model
adjusted for potential confounders was used to assess the risk of EOC due to endometriosis.
Results: The EOC incidence rate (IR) of the women with and without endometriosis was 11.64 and 2.66 per 10,000
person-years, contributing to a crude hazard ratio (HR) of 4.48 (95% confidence interval [CI] 2.84-7.06), and HR after
adjustment for all confounders (adjusted HR) of 5.62 (95% CI 3.46-9.14); the risk was higher in clear-cell carcinoma
subtypes (adjusted HR 7.36, 95% CI 1.91-28.33). The EOC IR of women with endometriosis consistently increased
with increasing age, ranging from 4.99 (<30 years) to 35.81 (≥50 years) per 10,000 person-years, contributing to a
progressively increased risk of EOC (crude HRs ranging from 2.80 to 6.74 and adjusted HRs ranging from 3.34 to 9.63)
compared to age-matched women without endometriosis, whose EOC IR also increased with age. The older women
(≥50 years) with endometriosis had a risk of EOC that was higher than both the age-matched women without
endometriosis (adjusted HR 9.63, 95% CI 3.27-28.37) and the youngest women (<30 years) with endometriosis
(adjusted HR 4.97, 95% CI 1.03-24.09).
Conclusions: These significant findings corroborate the previously reported association between endometriosis and
increased risk of EOC. Since the risk of EOC in women with a new surgico-pathological diagnosis of endometriosis
constantly increased with age and this increased risk of EOC was more significant in women aged ≥50 years, active
and intensive surgical intervention should be taken into consideration for older women with endometriosis.
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Many epidemiologic studies have supported the finding
that women with endometriosis may have an increased
risk of developing and/or being associated with epithelial
ovarian cancers (EOCs) [1-23]. However, nearly all evi-
dence has been obtained from Western countries [3-25].
A recent meta-analysis by Kim and colleagues investigat-
ing the impact of endometriosis on the risk and progno-
sis of ovarian cancer concluded that endometriosis is
strongly associated with an increased of ovarian cancer
but endometriosis may not affect disease progression
after the onset of ovarian cancer [25]. However, the risk
ratio (RR) was only 1.27 (95% confidence interval [CI]
=1.21-1.32) in case–control or two-arm cohort studies
and the standard incidence ratio (SIR) was 1.80 (95% CI
1.28-2.53), respectively [25]. The RR of “endometriosis-
associated EOC”, including endometrioid and clear-cell
subtypes of EOC in women with endometriosis, was
1.76 (95% CI 1.55-2.00) and 2.61 (95% CI 2.23-3.05),
respectively [25].
Except the strong association between the clear-cell
subtype and EOC, all others seemed to be well under
the level that supports causality. Why did the data show
only a weak association between endometriosis and
EOC? Although it is difficult to respond to the above
question, a possible reason might be the heterogeneity
within the newly defined population, since clinical het-
erogeneity, when present, has implications for the design
of research studies [26-28]. For example, Buis and
colleagues found that an increased risk was found in
women with endometriosis when the definition of endo-
metriosis was based on self-report, medical records in-
formation at subfertility treatment and/or a nationwide
pathology database (HR 8.2, 95% CI 3.1-21.6) [22]. The
risk was especially high in women with pathologically-
confirmed endometriosis after subfertility treatment,
with a HR of 12.4 (95% CI 2.8-54.2) [22]. In addition,
previous studies might have been influenced by any one
or more of many factors, such as age, obstetric and gy-
necologic history (nulliparity, menstrual cycles, infertility
status, pelvic inflammatory disease [PID], or hysterec-
tomy history, the use of pills and tubal ligation) and
many chronic illnesses – such as cardiovascular disease
(CVD), diabetes mellitus (DM), chronic liver disease
(CLD), and rheumatic disease (RD), that might contrib-
ute to the estimation of cancer risk [14,20]. And, to
avoid surveillance bias for cancer, which may shorten
the time to cancer diagnosis and cause over-estimation
of risks, most studies excluded synchronous cases
(defined as having a time interval between the detection
of endometriosis and EOC of 6 to 12 months), resulting
in an under-estimation of the association. The aim of
this study was to investigate whether endometriosis was
really associated with EOC after adjusting the above-mentioned factors. In order to achieve our aim, we con-
ducted a large-scale, nationwide, controlled cohort study.
Methods
The source population consisted of nearly the entire
population of Taiwan (23 million inhabitants) and the
data was that of the research database of the Taiwanese
National Health Insurance (NHI) program from 1996 to
2010. The Longitudinal Health Insurance Database 2000
(LHID 2000) contains 1 million randomly sampled bene-
ficiaries. The data of the sampled subjects in the LHID
2000 are representative of all beneficiaries with regard to
age, sex, and insurance cost, which have been described
in detail before [29,30].
This was a retrospective cohort study. According to
the written operating procedures, Good Clinical Practice
(GCP), and the applicable regulatory requirements, this
study projected was approved by the Institutional Review
Board of Taipei Veterans General Hospital (Chairman,
Professor Shung-Tai Ho, VGHIRB No.: 2012-12-012BC),
and the board is organized under, and operates according
to International Conference on Harmonisation (ICH)/
WHO GCP and the applicable laws and regulations. The
National Health Research Institute in Taiwan permitted
the access to the data in the National Health Insurance
Research Database, and 29,725 women aged between 20
and 51 years were identified. Women without a visit to an
obstetrician or gynecologist during the study period were
excluded. In order to increase the validity of identifying
women with newly diagnosed endometriosis in the
administrative data set, only those women with a new
surgico-pathological diagnosis of endometriosis (Inter-
national Classification of Diseases, Ninth Revision, and
Clinical Modifications [ICD9-CM] code 617), regardless
of clinical diagnosis of endometriosis status, during the
period between January 1, 2000 and December 31, 2010
were included among the incident endometriosis women
(n =5,945).
To validate the surgico-pathological diagnosis of endo-
metriosis, surgical treatments for endometriosis especially
limited to the ovary, tube, and peritoneal cavity were also
recorded. These included laparoscopy (ICD9-CM codes
54.21) and laparoscopic surgery, such as laparoscopic lysis
of peritoneal adhesions (54.51), laparoscopic oophorec-
tomy (65.01), laparoscopic diagnostic procedures related
to the ovaries (65.13 and 65.14), laparoscopic local exci-
sion or destruction of the ovaries (65.23, 65.24, and 65.25),
laparoscopic unilateral oophorectomy (65.31), laparo-
scopic unilateral salpingo-oophorectomy (65.41), laparo-
scopic salpingo-oophoroplasty (65.76), and laparoscopic
lysis of adhesions to the ovary and fallopian tube (65.81).
Exploratory laparotomy, such as lysis of peritoneal adhe-
sions (54.59), oophorectomy (65.0), aspiration biopsy of
the ovary (65.11 and 65.12), local excision or destruction
Wang et al. BMC Cancer 2014, 14:831 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/831of the ovary (65.21, 65.22, and 65.29), unilateral oophorec-
tomy (65.3), unilateral salpingo-oophorectomy (65.49),
salpingo-oophoroplasty (65.73), and lysis of adhesions to
the ovary and fallopian tube (65.89), was also included.
However, to decrease the influence of hysterectomy, bilat-
eral salpingo-oophorectomy, and bilateral oophorectomy
on the development of future EOC, women with hysterec-
tomy, except those women with a diagnosis of invasive
EOC during the follow-up period, were excluded.
Each endometriosis case was matched with 4 female
controls by age, index year, obstetric history, frequency
of gynecological/obstetric providers’ outpatient visits,
contraception methods, socioeconomic status, work and
urbanization, which resulted in an overall sample size of
23,780 matched controls without endometriosis (Figure 1).
For the women with endometriosis, the index date was
the date of a new surgico-pathological diagnosis of endo-
metriosis. For the controls, the index date was the first
visit to an obstetric/gynecological provider or admission
during the study period.
EOC was initially detected using inpatients with a
surgico-pathological diagnosis and validated using the
major disease files (ICD-9-CM 183) from the Registry
for Catastrophic Illness Patients.
Starting from the cohort index date, the study subjects
were followed until hospitalization with EOC or to theFigure 1 Cohort flow chart illustrating the inclusion and exclusion ofend of the study (December 31, 2010), whichever came
first, if no EOC had occurred. The specific histologic
subtype distribution of EOC in women with and without
endometriosis came from the database of the National
Cancer Registration System [31]. The histological types
used were based on the World Health Organization Classi-
fication of Tumors [32], and included serous (8441/3,
8460/3, 8461/3), mucinous (8470/2, 8470/3, 8471/3, 8480/
3, 8482/3), endometrioid (8380/3, 8382/3, 8383/3), clear
cell (8310/3, 8313/3), malignant Brenner (9000/3), undif-
ferentiated (8020/3, 8021/3), and carcinosarcoma (8950/3,
8980/3, 8981/3). “Endometriosis-associated” EOCs, includ-
ing clear-cell and endometrioid-cell types, were reported to
be highly associated with endometriosis [10,17,23-25].
Patients without an EOC event were treated as censored
subjects. Dropouts or those who were lost to follow-up
were also treated as censored. Basic characteristics are pre-
sented as percentages. The incidence of EOC was com-
pared between the women with and without endometriosis
using the incidence rate (IR). The χ2 test was used to com-
pare the IR estimates of invasive EOC among subsamples.
The Cox proportional hazards model was used to calculate
the HR and 95% CI to determine whether newly diagnosed
endometriosis is a risk factor for EOC.
In order to handle the issue of matching, the robust
sandwich estimate of Lin and Wei [33] for the covarianceparticipants in the study.
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hypothesis and null hypotheses of individual parameters.
Variables adjusted in the Cox model were PID, infertility
status, CVD, DM, CLD and RD. Statistical analyses were
implemented with SAS version 9.3 (SAS Institute Inc.,
Cary, North Carolina, USA), STATA version 10.0 (STATA
Corp, College Station, Texas, USA), and SPSS version 20
(SPSS, Chicago, IL, USA).
Results
Seventy-five of the total 29,725 women had EOC between
2000 and 2010. The total person-years of follow-up were
168,927, including 33,519 for the women with a surgico-
pathological diagnosis of endometriosis and 135,408 for
the women without endometriosis. The women with
endometriosis had higher rates of comorbid PID, infertil-
ity, CVD, DM, CLD, and RD than did the women without
endometriosis (all p <0.0005) (Table 1).
The EOC IR of the women with and without a
surgico-pathological diagnosis of endometriosis was
11.64 and 2.66 per 10,000 person-years, respectively,
contributing to a crude HR of 4.48 (95% CI 2.84-7.06),
and HR after adjustment for confounders (adjusted HR)
of 5.62 (95% CI 3.46-9.14) (Table 2).
In an effort to clarify the role of age in the relation-
ship between endometriosis and EOC, we performed
subgroup analysis based on age, using 4 age groups
(those <30, 30–39, 40–49, and ≥50 years). The median
age of the women with and without endometriosis who
had a diagnosis of EOC was 43.6 and 43.3 years, respect-
ively, which was without statistical significance (p =0.8783).
The risks of EOC in the women with endometriosis in-
creased with increasing age. The EOC IR of the women
with endometriosis ranged from the lowest IR of 4.99 per
10,000 person-years at age <30 years to the highest IR of
35.81 at age ≥50 years (Table 3). Using the youngest group
(women <30 years) as the reference, the HRs (95% CI)
of the women with endometriosis aged 30–39, 40–49,
and ≥50 years were 1.74 (95% CI 0.38-7.96), 1.87 (95% CI
0.43-8.01), and 5.46 (95% CI 1.18-25.32), respectively, in
the crude model (p =0.0223). After adjustment for con-
founders, the adjusted HRs (95% CI) of women with endo-
metriosis aged 30–39, 40–49, and ≥50 years were 1.66
(95% CI 0.36-7.61), 1.70 (95% CI 0.38-7.59), and 4.97
(95% CI 1.03-24.09), respectively (p =0.0351). Both ana-
lyses revealed a risk of EOC in the women with endomet-
riosis that significantly increased with age (Table 3).
The risk of EOC in the women without endometriosis
also increased with age (IR of EOC in this population
ranged from 1.78 to 5.80 per 10,000 person-years in all
age groups), except those women aged between 30 and
39 years–it decreased in this group. In spite of an
increased EOC IR with increasing age in the women
without endometriosis, the women with endometriosisstill had a more progressively increased risk of EOC with
increasing age than the women without endometriosis
(crude HRs ranging from 2.80 to 6.74 and adjusted
HRs ranging from 3.34 to 9.63) (Table 4). Both the
crude (p =0.0015) and adjusted (p =0.0039) Cox models
were statistically significant. Our results suggested that
age was an important risk factor for EOC in women with
endometriosis, since older women with endometriosis
not only had the absolute highest risk of EOC (35.81
per 10,000 person-years of EOC IR), but also had a
more significantly increased risk of EOC than younger
women with endometriosis, with a HR of 4.97 (95% CI
1.03-24.09).
The role of follow-up time between enrollment and
the occurrence of EOC (interval) was investigated. The
median interval between the cohort index date and the
date of a surgico-pathological diagnosis of EOC for the
women with and without endometriosis was 505 days
(ranging from 5 to 3433 days) and 824 days (ranging
from 1 to 4095 days), respectively. There was a statistically
significant difference between the 2 groups (p =0.0396),
suggesting that women with endometriosis had a statisti-
cally significantly shorter interval in which to get EOC
than women without endometriosis did. In fact, the high-
est risk of EOC was found in the first-year follow-up. The
increased risk of EOC in the women with endometriosis
remained consistent and persistent, since they had a sig-
nificantly higher risk of EOC than the women without
during the subsequent follow-up period (≥ one-year
follow-up), with an adjusted HR of 3.32 (95% CI 1.48-
6.68), after excluding the EOC cases in the first year of
follow-up. All of this suggested that the women with
endometriosis really did have a higher risk of EOC than
the women without (Figure 2).
The median follow-up time for the women with and
without endometriosis was similar, and without a statis-
tically significant difference (2059 days, ranging from 3
to 4019 days vs. 2080 days, ranging from 1 to 5243 days,
respectively, p =0.2267). Furthermore, there was no
statistically significant difference in the median visits to
gynecologists between the 2 groups (8.9, ranging from 6
to 77 visits vs. 9.1, ranging from 6 to 77 visits, for the
women with and without endometriosis, respectively,
p =0.6881). We separated the follow-up intervals into
one and 2 years to test the IR of EOC in each group,
and found that the EOC IR of the women with endomet-
riosis was always higher than that of the women without,
contributing to a consistently and persistently higher risk
of EOC in the women with endometriosis than that in
the women without, regardless of the interval of follow-
up (p =1.000).
Finally, we investigated whether the increased risk of
EOC in women with endometriosis might be influenced
by the significantly increasing incidence of “endometriosis-
Table 1 Baseline characteristics of the study subjects
Total (n = 29725) Endometriosis patients (n = 5945) Controls (n = 23780) P-value
Person-years 168927 33519 135408
Variable n % n % n %
Catastrophic illness < 0.0001
EOC 75 0.25 39 0.66 36 0.15
No EOC 29650 99.75 5906 99.34 23744 99.85
Age* 0.0750
≤ 41 14877 50.05 2914 49.02 11963 50.31
e> 41 14848 49.95 3031 50.98 11817 49.69
SES 0.8868
≥ 40000 4579 15.40 911 15.32 3668 15.42
20000-39999 9790 32.94 1941 32.65 7849 33.01
< 20000 10236 34.44 2073 34.87 8163 34.33
Others 5120 17.22 1020 17.16 4100 17.24
Work 0.5954
Yes 27617 92.91 5514 92.75 22103 92.95
No 2108 7.09 431 7.25 1677 7.05
Urbanization 0.9752
Urban 9957 33.50 1991 33.49 7966 33.50
Suburban 12549 42.22 2504 42.12 10045 42.24
Rural 7219 24.29 1450 24.39 5769 24.26
PID < 0.0001
Yes 13647 45.91 4518 76.00 9129 38.39
No 16078 54.09 1427 24.00 14651 61.61
Infertility < 0.0001
Yes 1094 3.68 608 10.23 486 2.04
No 28631 96.32 5337 89.77 23294 97.96
CV disease < 0.0001
Yes 1133 3.81 290 4.88 843 3.54
No 28592 96.19 5655 95.12 22937 96.46
Diabetes mellitus < 0.0001
Yes 1820 6.12 448 7.54 1372 5.77
No 27905 93.88 5497 92.46 22408 94.23
Chronic liver disease 0.0002
Yes 477 1.60 128 2.15 349 1.47
No 29248 98.40 5817 97.85 23431 98.53
Rheumatic disease < 0.0001
Yes 796 2.68 235 3.95 561 2.36
No 28929 97.32 5710 96.05 23219 97.64
EOC: invasive epithelial ovarian cancer; SES: socio-economic status; PID: pelvic inflammatory disease; CV disease: cardiovascular disease.
*Age variable was matched by the exact year of age, but the table shows age quartile groups. The median age of women with and without endometriosis was
40.5 and 40.4 years of age, respectively (p = 0.3570).
Wang et al. BMC Cancer 2014, 14:831 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/831associated EOC”, such as endometrioid and clear-cell sub-
types [34-37]. As expected, women with endometriosis had
a higher risk of “endometriosis-associated” EOC (adjusted
HR 3.70, 95% CI 1.62-8.46), and the risk of clear-cellsubtypes was much increased (adjusted HR 7.36, 95% CI
1.91-28.33). By contrast, other cell-type EOCs might
not be associated with endometriosis, since there was
no statistically significant difference between the women
Table 2 Incidence and crude and adjusted risk of invasive
epithelial ovarian cancer, according to endometriosis
status
Patients with
endometriosis (n = 5945)
Controls
(n = 23780)




Crude HR (95% CI) 4.48 (2.84-7.06)* 1.00
Adjusted HR (95% CI) 5.62 (3.46-9.14)* 1.00
EOC: invasive epithelial ovarian cancer; HR: hazard ratio; 95% CI: 95%
confidence interval.
Adjusted for pelvic inflammatory disease, infertility status, cardiovascular
disease, diabetes mellitus, chronic liver disease, and rheumatic disease.
*P < 0.001.
Wang et al. BMC Cancer 2014, 14:831 Page 6 of 10
http://www.biomedcentral.com/1471-2407/14/831with and without endometriosis (adjusted HR 0.948, 95%
CI 0.27-3.28).
Discussion
Although many studies have supported the positive asso-
ciation between endometriosis and EOC, many uncer-
tainties remain. One is the very low risk of developing
EOC from endometriosis, estimated at a <1.5% lifetime
probability, compared with 1% in the general female
population [38]. In addition, co-morbidities of endomet-
riosis, such as primary infertility, seemed more likely to
carry a risk of EOC [20]. Many infertility studies have
shown no association between endometriosis and EOC
[18,21]. Furthermore, contraception methods (tubal
ligation, oral pills, etc.), especially the use of oral pills,
which might be prescribed for treating symptoms of
endometriosis, are inversely related to the risk of EOC
[14,39]. Finally, hysterectomy and/or bilateral salpingo-
oophorectomy might have a protective effect on the
occurrence of EOC [23,35]. The strength of this study was
that surgical confounders, such as tubal ligation, hysterec-
tomy, and bilateral salpingo-oophorectomy were well
controlled, because they had been excluded in this study.
This study has another important strength, that is, it
might be the first nationwide, population-based study in
an Asian country. One study was conducted in Japan,
but it might not be representative of the generalTable 3 An increased risk of epithelial ovarian cancer in wom
Age < 30 years Age 30-39 years
n = 573 n = 1791
IR 4.99 9.89
Crude HR (95% CI) 1.00 (Reference) 1.74 (0.38-7.96)
P** 0.4729
Adjusted HR (95% CI) 1.00 (Reference) 1.66 (0.36-7.61)
P** 0.5154
IR: incidence rate (incidence per 10,000 person-years); HR: hazard ratio; *P: compari
group (age < 30 years).population of women with “endometriosis” in Asia [1].
In the Japan study [1], the diagnosis of “endometriosis”
was made by ultrasound, the disease was limited to the
ovary, and only 1/3 of cases had surgical confirmation.
In our study, all subjects with endometriosis were found
in an administrative data set, and all of the women had a
new surgico-pathological confirmation, including nearly
half who were diagnosed as having ovarian endome-
trioma (data not shown). Buis and colleagues found that
the increased risk was especially high in women with
pathologically-confirmed endometriosis after subfertility
treatment, with an HR of 12.4 (95% CI 2.8-54.2), com-
pared with an HR of 8.2 (95% CI 3.1-21.6) in women
whose endometriosis was diagnosed by self-report or
medical record information at subfertility treatment
and/or in the nationwide pathology database [22], sug-
gesting that a bias of selected subjects for either the
study group or the control group might significantly in-
fluence the risk estimation. Although the strict criterion
of “a surgico-pathological diagnosis” of endometriosis
might exaggerate the incidence rate of EOC in the endo-
metriosis arm of the study, with a subsequently inflated
risk of EOC in this arm, the risk of EOC in women with
endometriosis in the current study was still far lower
than in Buis and colleagues’ report (HR 5.62 vs. HR
12.4). In addition, Melin and colleagues [11] showed that
women who underwent unilateral oophorectomy for
endometriosis or radical surgical excision of all visible
endometriosis had a significantly reduced risk of later
development of EOC, with adjusted odds ratios of 0.19
(95% CI, 0.08–0.46) and 0.30 (95% CI, 0.12–0.74), re-
spectively, compared with controls. In our current study,
we did not analyze the effect of different surgical proce-
dures in the management of endometriosis, and we be-
lieve that some of the women may have been treated
with unilateral salpingo-oophorectomy or radical surgi-
cal excision, which might be a protective procedure
against the occurrence of EOC, but we still found that
those women with a new surgico-pathological diagnosis
of endometriosis had a persistently and consistently
higher risk of later development of EOC during the fol-
low up in the current study. Finally, after adjustment ofen with endometriosis with age
Age 40-49 years Age ≥ 50 years P*
n = 3023 n = 558
10.66 35.81
1.87 (0.43-8.05) 5.46 (1.18-25.32) 0.0223
0.4022 0.0302
1.70 (0.38-7.59) 4.97 (1.03-24.09) 0.0351
0.4853 0.0465
son among all groups. **p: comparison between study group and reference
Table 4 Incidence and crude and adjusted risk of invasive epithelial ovarian cancer, according to age
Age < 30 years (n =3148) Age 30-39 years (n = 9310) Age 40-49 years (n = 13747) Age ≥ 50 years (n = 3520)
Patients Controls Patients Controls Patients Controls Patients Controls
Diagnosis of EOC
Yes 2 3 10 4 18 22 9 7
No 571 2572 1781 7515 3005 10702 549 2955
IR 4.99 1.78 9.89 0.96 10.66 3.38 35.81 5.80
Crude HR (95% CI) 2.80 (0.47-16.74) 1.00 13.80 (3.80-50.11)** 1.00 3.03 (1.62-5.64)* 1.00 6.74 (2.51-18.10)* 1.00
Adjusted HR (95% CI) 3.34 (0.54-20.60) 1.00 19.41 (5.02-75.10)** 1.00 3.41 (1.76-6.61)* 1.00 9.63 (3.27-28.37)** 1.00
Patients: women with endometriosis; Controls: women without endometriosis; EOC: epithelial ovarian cancer; IR: incidence rate (incidence per 10,000 person-years);
HR: hazard ratio; CI: confidence interval; *P < 0.001, **P < 0.0001.
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a much higher risk of EOC than the women without
(adjusted HR 5.62, 95% CI 3.46-9.14 vs. crude HR 4.48,
95% CI 2.84-7.06), suggesting that women with a new
surgico-pathological diagnosis of endometriosis indeed
have a higher risk of EOC than women without.
The other argument, that the highest proportion of
EOC was diagnosed in the first year of follow-up, includ-
ing 29 of the 39 EOCs in the women with a new
surgico-pathological diagnosis of endometriosis and 22
of the 36 EOCs in the women without, contributing to
an unusually high IR of EOC in both groups, was raised.
Furthermore, the some of the women had a diagnosis of
EOC immediately within the enrolment period. Twenty-
four and fifteen patients with EOC were found in the
women with and without a new surgico-pathologicalWomen with 
endometriosis
Number 5945 4923 3
EOC events 29 4
Controls
Number 23780 19756 1
EOC events 22 4
Figure 2 The relationship between enrollment in this cohort and thediagnosis of endometriosis, respectively (p =0.0853), if
we defined that the enrolment period was less than
90 days. An additional argument was that all women
with endometriosis had a surgery, but not all of the
controls did. It is possible that the women underwent
surgery for a clinical diagnosis of endometriosis but
were found to have cancer, resulting in more EOC
patients in the endometriosis arm being detected. The
number of cases of endometriosis was a quarter of
cases in the women without endometriosis and every
change by one case in the incidence (cancer) of women
with a new surgico-pathological diagnosis of endometri-
osis would exaggerate the incidence ratio fourfold. All of
this emphasized the potential risk of biases secondary to
surveillance, including surgery, symptoms, and frequency
of gynecologist/obstetrician visits in our current study.876 2799 1741 597
3 2 1 0
5591 11239 6991 2402
6 2 1 1
occurrence of epithelial ovarian cancer.
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was to determine the risk of EOC due to endometriosis
in Taiwanese women. Therefore, a surgico-pathological
procedure, which is a “gold-standard” tool to diagnose
endometriosis [40], should be performed. The IR of EOC
in the women either with or without endometriosis was
relatively evenly distributed in their own group, and the
EOC IR of the women with endometriosis was always
higher than that of the women without, contributing to a
consistently and persistently higher risk of EOC in the
women with endometriosis than in the women without,
regardless of the interval of follow-up (p =1.000). In
addition, after excluding EOC cases during the first-year
follow-up, the median time between enrolment and
occurrence of EOC in both groups was similar, without
a statistically significant difference (1296 vs. 1402 days,
p =0.8979), suggesting that the increased risk of EOC
in women with a new surgico-pathological diagnosis of
endometriosis may be irrelevant to surgery. All this
suggested that endometriosis itself had a strong associ-
ation with EOC, not only for a synchronous tumor
(EOC arising from endometriosis), but also for any
newly developed EOC.
Along with the findings of Kobayashi [1] and Pearce
[16], our results supported the lack of an association
between follow-up time and risk of EOC. There was no
statistically significant difference in the frequency of
visits to gynecologists between women with and without
endometriosis during the follow-up period (8.9 vs. 9.1
visits, p =0.6881), which further supported the likelihood
that the increased risk of EOC in women with endometri-
osis might not be biased by surveillance. Our above-
mentioned results did not support the findings in Melin’s
[9] and Brinton’s reports [4,7] showing the existence of an
increased risk of EOC as follow-up time increased (HR of
1.43 increased to 2.23) [9].
Investigating the contribution of age to the associ-
ation between endometriosis and EOC was another of
this study’s strengths. The risk of EOC was found to
increase with the increase in age at diagnosis of ovarian
endometrioma [1]. Women above 50 years of age had a
higher HR of 13.2 (95% CI 6.90-20.9) [1]; Melin and
colleagues had a similar finding [9]. Our study findings
supported these previously published data. The abso-
lute EOC IR of women with endometriosis consistently
and persistently increased with increasing age (from the
lowest IR of 4.99 per 10,000 person-years in women
aged <30 years to the highest IR of 35.81 person-years
in women aged ≥50 years). Using women with endo-
metriosis <30 years old as a reference to perform risk
estimation, we found that women with endometriosis
aged ≥50 years had a statistically significantly increased
risk of EOC (adjust HR 4.97, 95% CI 1.03-24.09,
p =0.0465).There were some limitations in our current study.
First, we excluded women who had endometriosis diag-
nosed before the year 2000, and of the most importance,
only women who had a surgico-pathological diagnosis of
endometriosis were enrolled into the study. Therefore,
some women who may have had endometriosis were
excluded from this study, due to the absence of a
surgico-pathological confirmation. In addition, as shown
above, these women may have undergone unilateral
salpingo-oophorectomy or radical surgical excision of all
visible endometriosis, which might have decreased the
risk of EOC [11]. Second, we excluded women with a
possibly high or low risk of EOC. For example, women
who never visited a gynecologist were excluded in our
original design.
Third, we did not evaluate how many women regardless
of endometriosis status had visited physicians for ante-
natal check-up or for pill refills during the study period. In
addition, we did not investigate the yes/no and time
course of the use of oral pills, which might have had a
protective effect against the occurrence of EOC, and the
protection might have been stronger in those women with
long-term use [14,39]. It is reasonable to suppose that
women with endometriosis might have a more pro-
nounced trend and longer interval in the use of pills for
symptom control [41]. However, we used the following
strategies, including (1) the exclusion of women without a
gynecologist visit; and (2) a 1:4 match by obstetric history
and frequency of gynecological/obstetric providers’ out-
patient visits. Both might minimize the potential biases of
surveillance or the frequency of medical care. We believed
that the frequency of antenatal check-up and/or health
consultation would be similar between both groups.
Fourth, we did not investigate the main symptoms of the
women seeking gynecologic services. Some of them might
have presented with persistent symptoms, which might
overestimate the risk. And, some of them might have
already had a co-existing EOC, which might further over-
estimate the risk of EOC in women with endometriosis.
The inherent main symptoms of the women with and with-
out endometriosis visiting gynecologists might be different.
For example, women with endometriosis might frequently
have complaints of dysmenorrhea and abdominal pain.
Our data also showed the significant difference in baseline
characteristics in both groups. The women with endomet-
riosis had higher rates of comorbid PID, infertility, CVD,
DM, CLD, and RD than the women without (Table 1).
However, after adjustment of all confounders, the adjusted
HR was even higher than the crude HR. Finally, the EOC
IR of women without endometriosis was similar to that of
the database of the National Cancer Registration System
[31]. All of this supported the existence of an actual risk
of developing EOC among women with a new surgico-
pathological diagnosis of endometriosis.
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Although many uncertainties could not be totally avoided
in our current study, our findings corroborate a previously
reported association between endometriosis and an in-
creased risk of EOC. The risk of EOC in women with a
new surgico-pathological diagnosis of endometriosis was
consistently and persistently higher than that in women
without endometriosis, regardless of age and follow-up
period, and the risk was particularly high in the older
population (≥50 years). This population group was appar-
ently at risk of EOC because of their higher incidence rate
in absolute terms and comparably higher risk of EOC than
that of age-matched women without endometriosis and/
or younger women with endometriosis. Active and inten-
sive surgical intervention should be considered with these
older women with endometriosis if they do not have other
contraindications for surgery.
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